Haemonetics Corporation Stock Price and Value Analysis

Should you buy Haemonetics Corporation stock? (NYSE:HAE). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the HAE Numbers

HAE Price
(Haemonetics Corporation stock price per share)
[?] HAE Fair Price
(based on intrinsic value)
[?] HAE Safety Price (based on a variable margin of safety) $15.98
[?] PE Ratio versus Sector 79% higher than other Healthcare stocks
[?] PE Ratio versus Industry 51% higher than other Medical Instruments & Supplies stocks
[?] Cash Yield 2.33%
[?] Free Cash Flow Jitter 80%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 1,642,362 shares shorted. With 50,972,722 shares available for purchase and an average trading volume over the past 10 trading days of 290,180, it would take at least 5.66 days for all of the short holders to cover their shorts.

Is Haemonetics Corporation Stock on Sale?

We believe that Haemonetics Corporation may be worth examining further. It's making money, which is a very positive sign. Is it on sale?

Haemonetics Corporation looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.

Should You Buy HAE Stock?

Does Haemonetics Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.